Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (6729)	5/31/1999 5:05:00 PM
From: John Zwiener	Read Replies (2) \| Respond to of 9719

Three to consider: CAMH detects T-wave alternans (TWA) and has recent FDA approval to claim a patient positive for TWA is at risk for sudden death due to arrythmia. Just made agreements with Guidant and Medronic for codistribution/education of CH2000 for detecting TWAs. Looks like another biotech sleeper. IGEN. It's been a year since Igen made it's big move from 5. It is 29 at this time. It could trade around here for awhile, but it may not. There will probably be a settlement with Roche in which a dividend could be close to the stocks' present price. In addition, it looks like it could be a significant player in high through put screening with agreements with about 10 pharmacuetical companies so far, and has placed at least 2, with a total of 13 to be placed by end of June. The USDA lists their E. coli screening test prominently at the USDA site--indicates the test is 10,000 times more sensitive, and the study they did showed that Igen detected 28 contaminated sample versus only 8 for the next best test, plus no false positives while the nearest competition has a couple. Many other tests in progress for food and water testing. USDA testing for making it part of their field testing with industry likely to follow if it becomes the standard. Igen also has 300 instruments in POC settings because of winning injunction against Roche, and may speed up portable POC instrument. Other things have moved forward. Also raised 30 million at 8.5% interest for 5 years to advoid dilution; this may indicate financier and Igen will have no trouble paying the money back. Sepracor. I know the porfolio already has this, but this seems like a good chance to add to holdings even though the price could try to take another dip. Analysts negative on sepracor seem to be resorting to falsehoods and facts taken out of context; meanwhile, much of the risk has been taken out by the price drop.